Xenon Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 19 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -58.87%
- Profit Growth -15.89%
- Ebitda -16.93%
- Net Worth 43.17%
- Total Assets 14.07%
About Xenon Pharma
Xenon Pharma Private Limited (XPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 24 August 2005 and has a history of 19 years and six months. Its registered office is in New Delhi, Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Naresh Kumar and Karmveer Singh serve as directors at the Company.
Company Details
- Location
New Delhi, Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24233DL2005PTC139951
- Company No.
139951
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Aug 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
What products or services does Xenon Pharma Private Limited offer?
Xenon Pharma Private Limited offers a wide range of products and services, including Common Disease Medicines, Antihistamines, Cardiovascular Drugs & Medication, Cholesterol Medicine, Pain Relief Drugs & Pharmaceuticals, Diclofenac, Pharmaceutical Medicine, Brain & Nervous System Drugs, Antiepileptic Drugs, Blood Pressure Medicine.
Who are the key members and board of directors at Xenon Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Naresh Kumar  | Director | 19-Jan-2012 | Current |
| Karmveer Singh | Director | 31-Mar-2018 | Current |
Financial Performance of Xenon Pharma.
Xenon Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 58.87% decrease. The company also saw a substantial fall in profitability, with a 15.89% decrease in profit. The company's net worth Soared by an impressive increase of 43.17%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Xenon Pharma?
In 2022, Xenon Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Xenon Pharma?
Unlock and access historical data on people associated with Xenon Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Xenon Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xenon Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
